Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments.
about
SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasisMathematical modeling of bacterial kinetics to predict the impact of antibiotic colonic exposure and treatment duration on the amount of resistant enterobacteria excretedDistinguishing Antimicrobial Models with Different Resistance Mechanisms via Population Pharmacodynamic ModelingIdentification of the primary mechanism of action of an insulin secretagogue from meal test data in healthy volunteers based on an integrated glucose-insulin model.Pharmacokinetic and pharmacodynamic modeling of cyadox against Clostridium perfringens in swine.Semimechanistic pharmacokinetic-pharmacodynamic model with adaptation development for time-kill experiments of ciprofloxacin against Pseudomonas aeruginosa.Discovery of novel orally bioavailable oxaborole 6-carboxamides that demonstrate cure in a murine model of late-stage central nervous system african trypanosomiasis.Mathematical modeling to characterize the inoculum effect.Adenylate kinase release as a high-throughput-screening-compatible reporter of bacterial lysis for identification of antibacterial agents.In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TBA population pharmacokinetic modeling approach shows that serum penicillin G concentrations are below inhibitory concentrations by two weeks after benzathine penicillin G injection in the majority of young adults.Empirical mode decomposition and k-nearest embedding vectors for timely analyses of antibiotic resistance trends.Predicting in vitro antibacterial efficacy across experimental designs with a semimechanistic pharmacokinetic-pharmacodynamic model.Pharmacokinetic-pharmacodynamic model to evaluate intramuscular tetracycline treatment protocols to prevent antimicrobial resistance in pigs.Two mechanisms of killing of Pseudomonas aeruginosa by tobramycin assessed at multiple inocula via mechanism-based modeling.Pharmacokinetics/pharmacodynamics of colistin and imipenem on mucoid and nonmucoid Pseudomonas aeruginosa biofilms.Modeling the growth dynamics of multiple Escherichia coli strains in the pig intestine following intramuscular ampicillin treatment.Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial killMechanism-based pharmacokinetic-pharmacodynamic models of in vitro fungistatic and fungicidal effects against Candida albicans.A multistate tuberculosis pharmacometric model: a framework for studying anti-tubercular drug effects in vitro.Quantifying subpopulation synergy for antibiotic combinations via mechanism-based modeling and a sequential dosing designA simple in vitro PK/PD model system to determine time-kill curves of drugs against Mycobacteria.In vitro pharmacodynamic models to determine the effect of antibacterial drugs.The multistate tuberculosis pharmacometric model: a semi-mechanistic pharmacokinetic-pharmacodynamic model for studying drug effects in an acute tuberculosis mouse model.Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies.Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization.Pharmacokinetics and pharmacodynamics in antibiotic dose optimization.Translational Pharmacometric Evaluation of Typical Antibiotic Broad-Spectrum Combination Therapies Against Staphylococcus Aureus Exploiting In Vitro InformationA mechanism-based pharmacokinetic/pharmacodynamic model allows prediction of antibiotic killing from MIC values for WT and mutants.Translational PK/PD of anti-infective therapeutics.A pharmacokinetic-pharmacodynamic model characterizing the emergence of resistant Escherichia coli subpopulations during ertapenem exposure.Simulation-Based Evaluation of PK/PD Indices for Meropenem Across Patient Groups and Experimental Designs.Antibacterial Activity of 7-Epiclusianone and Its Novel Copper Metal Complex on Streptococcus spp. Isolated from Bovine Mastitis and Their Cytotoxicity in MAC-T Cells.Pharmacokinetic-pharmacodynamic model for gentamicin and its adaptive resistance with predictions of dosing schedules in newborn infants.The PK/PD Interactions of Doxycycline against Mycoplasma gallisepticum.Dynamic interaction of colistin and meropenem on a WT and a resistant strain of Pseudomonas aeruginosa as quantified in a PK/PD model.Effect of protein binding on the pharmacological activity of highly bound antibiotics.High β-lactamase levels change the pharmacodynamics of β-lactam antibiotics in Pseudomonas aeruginosa biofilms.Pharmacokinetic-pharmacodynamic modeling of the in vitro activities of oxazolidinone antimicrobial agents against methicillin-resistant Staphylococcus aureus.Population pharmacokinetic modeling of tramadol and its O-desmethyl metabolite in plasma and breast milk.
P2860
Q21144510-A2CBEE65-726C-433D-968C-D30E60A39544Q28542920-EFAAF195-F16F-44E0-AE40-C5166B913E15Q28550711-D973C7B7-9A98-415C-9CA4-F69ADD5AC329Q30578482-4EE4BA51-AF86-41D2-A141-FA3CEA36604DQ33826396-479E5BB8-9B00-406F-A873-F8FCF1783AF0Q33876563-473451D8-E331-4233-8916-6139992D4952Q34150973-3783B591-8F07-4EF6-833C-FD89F8D3D669Q34290045-8ADA9A89-C6E7-41A8-B06C-302BE681C2F2Q34425938-5EEF0338-F7E8-4A41-A18A-6B874D6B1076Q34591451-CC06FF68-7D04-491E-A65D-0D93CEC25CA3Q34596526-6BE5210C-6F63-42D8-B584-9A1F6C203E08Q34700131-9FCE56E2-B250-4972-8550-78B7A8AE3D8AQ34737629-AB2BCE80-4F4C-4FE9-9E2B-1CA2786BBA9DQ35076904-F1CFDA09-52D5-4460-A0EA-12EECE0541C8Q35168882-8BEA79E3-71FD-47DB-8F2E-89D7B08DC490Q35191390-C5EB9A8B-A809-44B8-94EC-6984B0056085Q36124204-6BE6E4D3-EA2D-4813-B3B8-8DDAFF051612Q36171772-6865C934-BCEC-4511-9F77-B005C35CCE1EQ36482785-E69B2B20-4382-4ABF-80CF-0697FFD8FD55Q36684146-3B466F8C-E075-4A23-8CCE-5A2AC33BCB46Q36785827-E5775EE3-11F9-4F9E-9732-89745DE58038Q37441394-73D8CA4B-21CB-4D57-9574-8AC1B113366BQ37660762-D1878DE6-5B4D-4AD8-B388-9768CC077417Q37733488-A5E7F0F0-A2AF-4E72-8850-3936F112983FQ38420688-2E3FE11C-69E6-4904-9BE6-A5BE11B3FE70Q38626980-83F9F863-6D43-4BE4-B5F3-2F6554D73DD6Q38664871-DB3976E8-3FB7-4173-8E6C-E9F7C377A432Q38853629-BDD75953-93F1-4B1F-B668-146C13DAE236Q38966188-5BABFD95-080E-4FA1-9355-139C00AD894FQ39039505-1B61FA55-F593-46E2-A799-22FA44472AD2Q39665401-C79C791E-35E3-474D-9C23-A9F48F49CC6EQ40087805-77977694-94DD-44D5-8D7B-B857EAB56456Q40209447-252DCB09-E115-42F6-BC4B-477266CEF0FBQ40326667-7EE166E7-9A5B-469C-8FA4-C28D6091BBD9Q40666520-066887A4-9927-47F1-A120-3CA739B8C574Q40802708-DC81D836-AE55-49A2-97CF-93B46055E040Q42015540-E347FA30-497C-44BB-A491-AB2D4E16A2D9Q42529536-27F9BBEC-07C4-4CDD-851F-23F94397A916Q42687502-82FA2ECC-E3FA-4DED-8827-1678033E2745Q43884622-573818FE-61A2-4B22-BEF3-2DDC8FB2FD41
P2860
Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Semimechanistic pharmacokineti ...... m time-kill curve experiments.
@ast
Semimechanistic pharmacokineti ...... m time-kill curve experiments.
@en
type
label
Semimechanistic pharmacokineti ...... m time-kill curve experiments.
@ast
Semimechanistic pharmacokineti ...... m time-kill curve experiments.
@en
prefLabel
Semimechanistic pharmacokineti ...... m time-kill curve experiments.
@ast
Semimechanistic pharmacokineti ...... m time-kill curve experiments.
@en
P2093
P2860
P356
P1476
Semimechanistic pharmacokineti ...... m time-kill curve experiments.
@en
P2093
Anders Viberg
Elisabet I Nielsen
Elisabeth Löwdin
Marie Sandström
Mats O Karlsson
P2860
P304
P356
10.1128/AAC.00604-06
P407
P577
2006-10-23T00:00:00Z